Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...

Chronic Obstructive Pulmonary Disease II: Emphysema

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Advances in Sarcoidosis.

Archivos de bronconeumologia·2026

Same author

KL-6 as a Biomarker for Adult Patients with Cystic Fibrosis and the Impact of <i>MUC1</i> Genotype.

Journal of clinical medicine·2026

Same author

Olive Oil and the Impact of Gastrointestinal Adverse Events During Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis: A Post-hoc Analysis of the MADIET Trial.

Archivos de bronconeumologia·2026

Same author

Toll interacting protein (TOLLIP) serum concentration in patients with systemic sclerosis (SSc), with and without interstitial lung disease (ILD).

BMJ open respiratory research·2026

Same author

Targeting CXCR6 suppresses granuloma formation and pulmonary fibrosis through inhibiting Th17 responses in sarcoidosis.

International immunopharmacology·2026

Same author

Idiopathic pulmonary fibrosis risk loci in East Asian populations mirror those of European populations.

American journal of respiratory and critical care medicine·2026

Same journal

Pneumonia Reimagined: Host, Microbe, and the Shifting Landscape of Disease.

Clinics in chest medicine·2026

Same journal

Advocacy in Pneumonia.

Clinics in chest medicine·2026

Same journal

Vaccines Against Pneumonia: Current Updates.

Clinics in chest medicine·2026

Same journal

Non-antibiotic Treatments for Pneumonia: Host-Directed Therapies, Next-Steps and Future Directions.

Clinics in chest medicine·2026

Same journal

Customizing Antibiotic Treatment for Pneumonia: Can We Have a Single Unified Algorithm for All Types of Pneumonia?

Clinics in chest medicine·2026

Same journal

The Role of Complex Digital Interventions to Improve Pneumonia Care.

Clinics in chest medicine·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 24, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Chronic hypersensitivity pneumonitis.

Ulrich Costabel¹, Francesco Bonella, Josune Guzman

¹Department of Pneumology/Allergy, Ruhrlandklinik, University Hospital, Essen, Germany. ulrich.costabel@ruhrlandklinik.uk-essen.de

Clinics in Chest Medicine

|February 28, 2012

Summary

This summary is machine-generated.

Hypersensitivity pneumonitis (HP) is an immune response to inhaled antigens. Identifying and avoiding the trigger antigen is key for managing chronic HP, which can resemble idiopathic pulmonary fibrosis and predict mortality.

More Related Videos

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

Related Experiment Videos

Last Updated: May 24, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

Area of Science:

Pulmonology
Immunology
Environmental Medicine

Background:

Hypersensitivity pneumonitis (HP) is an immune-mediated lung disease triggered by inhaled environmental antigens.
Chronic HP can present similarly to other interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF).
Identifying the causative antigen is crucial for diagnosis and management, while antigen avoidance is critical for treatment.

Purpose of the Study:

To highlight the diagnostic challenges of chronic HP, particularly its mimicry of IPF.
To emphasize the prognostic significance of pulmonary fibrosis in HP.
To underscore the need for further research into the pathogenesis of HP and its progression.

Main Methods:

Review of clinical presentations and diagnostic criteria for HP.
Analysis of imaging findings (high-resolution computed tomography) and histopathology in HP.
Discussion of current treatment strategies, focusing on antigen avoidance.

Main Results:

Pulmonary fibrosis, evident on biopsy or HRCT, is a significant predictor of mortality in HP.
Chronic HP can progress even without ongoing antigen exposure, indicating complex disease mechanisms.
Only a subset of exposed individuals develop HP, suggesting genetic or other predisposing factors.

Conclusions:

Early recognition and antigen avoidance are paramount in managing hypersensitivity pneumonitis.
Pulmonary fibrosis in HP carries a poor prognosis, necessitating further investigation.
Understanding the factors contributing to HP development and progression requires additional research.